EAN News

  The democratic body of the European Academy of Neurology (EAN) is the assembly of delegates, which acts as the parliament of the EAN. This assembly meets once a year, usually on Saturday, during the annual meeting. The 4 major… Continue Reading

The EAN established an office in Brussels located within the University Foundation a long time established institution founded in 1920 to promote scientific activity at Belgian universities. Over time, this scope was enlarged and the Foundation now hosts an important number of academic societies such as EAN, FENS - Federation of European Neuroscience Societies, EURORDIS – European Organisation for Rare Diseases, EPA – European Psychiatric association etc.

Starting at the EAN congress 2018 in Lisbon, the EAN Teaching Course sub-Committee has proposed to have an educating AND entertaining quiz-show. A dedicated taskforce together with the support of the EAN Scientific Panels worked on the set-up of this educational session – the EAN BrainChallenge.

Prof. David B. Vodušek (DVB): Dear Prof. Zuberi I congratulate you with your new position as President of the EPNS. EAN addresses clinical neurology and needs to broaden its spectrum also towards clinical neuro-pediatrics. Kindly introduce the EPNS and its work to the readers of the EAN Pages Prof. Sameer Zuberi (SZ): Thank you. It is a special honour and a privilege for me to be elected as President of the EPNS. Our outgoing President, Lieven Lagae, deserves an enormous thank you from all of us— for guiding the society so ably.

As in the previous years, EANpages asked EAN committee members, panel chairs, and invited speakers  which session one should not miss at the upcoming congress in Lisbon 2018. Please find their answers below!   Rolf Fronczek, MD, PhD
Dept. of… Continue Reading

  Portugal has a long tradition in the study of behavioral disorders, dating back to the work of Egas Moniz and his attempt to improve some psychosis with psychosurgery. In the early 1970’s Antonio Damasio, who was taking his PhD… Continue Reading

As every year, spring time is high season for preparing for the annual congress - this year the 4th congress of the European Academy of Neurology in Lisbon. It is the annual main event of our Society and we expect around 6000 participants in this special and historically attractive Portuguese capital. The congress has continuously adapted its profile and one of the main goals of our Society is to continuously develop new formats which satisfy the requests of modern neurology and its drivers, the European Neurologists. Our program committee under the leadership of Prof. Boon has excellently realized this request with many new innovations.

For May 2018, we have selected: Kappos L, Bar-Or A, Cree BAC, et al., for the EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet Neurol 2018;391:1263-1273. Secondary progressive multiple sclerosis (SPMS) is characterized by a previous history of relapsing remitting MS (RRMS) and the continuous progression of disability over the years typically without relapses.

Portugal is a country with a 900-year history: many remnants of past colonization by Celtics, Romans, and Arabians are still present. Unquestionably, the greater contribution of Portugal to the humanity have been the overseas navigations around the world, namely the discovery of the maritime way to India, the discovery of Brazil and of several Atlantic islands.

Education is one of the key elements of the activities of the European Academy of Neurology. While the congress is well known to most of our members and European Neurologists the activities outside the congress are much less known. EAN has a special committee working on education[1] with Prof. Hannah Cock as the chair and the teaching course subcommittee under the leadership of Prof. Claudia Sommer. They are charged to develop an educational program including education for neurologists in training and advanced courses with the emphasis on training for the general neurologist. While the field of Neurology is getting increasingly broader it is of paramount importance to set a common ground for all neurologists which our education committee has carefully developed. For the congress educational programme, a five-year curriculum of the educational content covering all relevant topics has been developed over the past 3 years and parts of this plan are also applied to the educational activities outside the congress.

Prof. Wolfgang Oertel (WO): Dear Prof. Di Luca I congratulate you with your new position and kindly ask you to illustrate your plans for EBC’s strategy and work in the years to come. Prof. Monica Di Luca (MDL): Being elected as President of EBC is a great honour for me as well as an important challenge. This is an important era for EBC. Thanks to the excellent work of the past President David Nutt, the last 4 years witnessed the consolidation of our Council in the European scenario as the ideal platform where all voices related to brain research could find an interlocutor and could merge. We are now in the privileged position to start new projects and bring EBC to a next step.

History Machado-Joseph disease (MJD) is an autosomal dominant (AD) spinocerebellar ataxia (SCA) initially described in descendants of immigrants from the Portuguese islands of the Azores. It was in 1972 that Kenneth K. Nakano and colleagues described the Machado family, with an AD, late onset, cerebellar ataxia with peripheral neuropathy. All family members were descendants from Guilherme Machado, who had migrated from São Miguel (Azores) to Massachusetts in the late nineteenth or early twentieth centuries.